Introduction
Sickle-cell disease is a term used to denote a group of inherited disorders occurring mainly in Negro peoples and characterised by a predominance of haemoglobin S (Hb S) in the red cells. The major conditions included in this group are homozygous sickle-cell anaemia (Hb SS), sickle-cell/p-thalassaemia double heterozygosity, sickle-cell/haemoglobin C disease (Hb SC), and the combination of sickle-cell trait and heterozygous hereditary persistence of fetal haemoglobin. In Britain, where the main wave of immigration occurred in the early 'sixties, few middleaged or elderly patients with sickle-cell disease are seen. The general impression seems to be that of a severe disease of children and young adults necessitating frequent admissions to hospital. Mann and Stuart' have provided the only data relating to the severity of the disease in Britain. In 18 children with sickle-cell disease they found a similar average number of sickle crises-three per patient per year-to that reported in a contemporary American study.2 The present investigation was undertaken in an attempt to establish further the characteristics of sickle-cell disease in Britain.
Patients and methods CASE FINDING Case finding was a retrospective study of data relating to 70 patients with sickle-cell disease who had at some time between 1962 and 1979 attended the Central Middlesex Hospital, a district general hospital in Brent. Fifty-three of the cases were on a register of patients with sickle-cell disease maintained by the haematology department since 1976, while the remaining 17 were traced from the Hospital Activity Analysis since 1971 and from the register of children with sickle-cell disease in Brent, which was started by the community child health department in 1973. A major difficulty with the last two sources arose from the confusion between sickle-cell disease and sickle-cell trait (Hb AS). For example, of 88 cases recorded in the Hospital Activity Analysis as having been admitted with sickle-cell disease, 57 actually had sickle-cell disease, 27 were Hb AS, and there was one case each of Hb C trait, glucose-6-phosphate deficiency, f-thalassaemia trait, and a white individual who had never been tested for Hb S. All but four of the patients traced from the three sources were recalled, and the diagnosis of sickle-cell disease was confirmed by haemoglobin electrophoresis, measurement of haemoglobins A2 and F, and Kleihauer staining of films for confirmation of the diagnosis of heterozygous hereditary persistence of fetal haemoglobin. All the patients are at present attending the paediatric or adult haemoglobinopathy clinic on a routine basis. Of the four patients who could not be recalled, three had died before the beginning of the study and one failed to attend for follow-up. antenatal or preanaesthetic testing. Thirty-two of the symptomatic cases were diagnosed during hospital admission, and six were referred to outpatient clinics because of sickle-cell-disease-related symptoms (joint pains, haematuria, or anaemia). patient-year) whereas the number of admissions declined to 0-4-0-6 per patient-year in those over the age of 10 (fig 1) . Two patients accounted for 33% of all admissions for sickle-cell disease, with 29 and 37 admissions respectively. One patient with asthma, a sibling of the second case, accounted for 63% of all non-sickle-cell disease admissions. The analysis of admissions in these two children is shown in fig 2. It is evident that they were admitted with increasing frequency after their eldest sister's death from sickle-cell disease. Before that, their frequency of hospital admission was similar to that of other patients with Hb SS of the same age group. originally from West Africa, the excess of Hb SC over Hb SS individuals cannot be explained on the basis of a greater prevalence of the Hb C gene in West African compared with West Indian populations. Patients with Hb SS were the most severely affected and tended to be diagnosed early; no patient with Hb SS was diagnosed on routine screening. Nevertheless, patients with Hb SS were admitted to hospital on average only once a year when under 5 years and once every two years in the older age groups. These findings are similar to those of Diggs and Flowers,4 who observed 22 admissions in 37 patients aged 2-20 years during a two-year period, and to those of Lubin and Oski,2 who reported 1 08 admissions per patient-year for 11 children aged 3J-17 years. Powars5 quoted a hospital admission frequency of 3-6 per decade after the first 5 years of life in a group of 422 children with sickle-cell disease.
In our series 74% of all admissions occurred in patients with Hb SS, who represented only 31% of all the patients. Painful crises and acute pulmonary involvement without demonstrable bacterial infection-the chest syndrome-accounted for more than 90% of the admissions in this group. These findings are similar to those in the American5 and Jamaican6 series.
Four pneumococcal infections occurred, all in children with Hb SS aged between 18 months and 8 years. Neither prophylactic penicillin nor pneumococcal vaccine had been administered in these cases. One of the infections was associated with a sequestration crisis but there were no deaths. In the Jamaican series7 nearly 10% of children with Hb SS died during the second six months of life, mainly from acute splenic sequestration and pneumococcal infections; further deaths occurred during the second and third years of life. This small study has shown that sickle-cell disease in people of West Indian and West African origin living in Britain is similar to the disease in American5 and Jamaican6 negroes. The numbers studied are not sufficiently large to allow assessment of mortality nor of features of prognostic significance. Nevertheless, two important points emerge:
(1) There are probably many undiagnosed asymptomatic individuals with sickle-cell disease of all age groups in the community. The main risk to such undiagnosed individuals is an unexpected, severe and potentially fatal sickling episode during pregnancy or after surgery (as in our case 2).
(2) The early identification, through cord blood screening, of infants with sickle-cell disease is essential if sickle-cell-diseaserelated deaths in infancy (estimated at around 10% of all infants with sickle-cell disease in Jamaica7 and America5 but not detected in our series presumably through lack of recognition) are to be prevented. In a short series of patients being operated on for morbid obesity, all of them weighing 126 kg or more, the spleen weighed three to four times normal size. The blood picture was normal. Is this observation of any importance or is spleen weight related to body weight ?
"Normal" spleen weight appears to be related to the age of the patient and decreases from 20-29 years and above 60 years of age. No pronounced variation in the weight of the normal spleen is seen in relation to body weight or height.' In the last 500 necropsies I have performed no correlation was seen between body and splenic weights. This series included one case of "morbid obesity" who died postoperatively. His splenic weight was 250 g, but this enlargement was adjudged to be in relation to an acute peritonitis and septicaemia. In irregular anovulatory cycles progestogens can be given to mimic the action of the corpus luteum and induce secretory change in the endometrium. Progesterone itself is inactive when taken by mouth, but various synthetic progestogens are available: most manufacturers recommend a 10-day course (day 16 to day 25 of the cycle) for this indication. To control irregular ovulatory cycles it may be necessary to give the progestogen from day 5 to day 25 of the cycle. After the tablets are stopped the endometrium is shed as in a normal period. Side effects include failure to control the menorrhagia, breast heaviness, loss of libido, and nausea. Progestogens are contraindicated in patients with liver disease. Taking the hormones for 14 days each month has no contraceptive effect. Progestogens should not be given for more than three months to control dysfunctional uterine bleeding without referral to a gynaecologist. One suspects that if the regimen is successful for 10 years it was not necessary in the first place, since severe menorrhagia usually breaks through the treatment. There is no published experience of continuing the regimen for 10 years or more, so we have to guess at the risks-remembering that the dosage of progestogen used to control menorrhagia is about 10 times that in the combined oral contraceptive and more than 20 times that in the progestogen-only contraceptive. Studies of the long-term risks of the pill indicate that the progestogen component is not associated with carcinogenesis or venous thromboembolism but may be associated with an increased risk of myocardial infarction.1 lVessey MP. Female hormones and vascular disease-an epidemiological overview.
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How should recurrent threadworm infestation be managed when all the usually accepted procedures have been tried unsuccessfully ?
